Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol Oral Solution (Epidiolex) in Rett Syndrome
NCT03848832Phase 3Terminated
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Jul 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in Rett syndrome (RTT) (3 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Rett Syndrome Behaviour Questionnaire Total Score at Week 24. Started Jul 2019; status: terminated.
02
Drugs
cannabidiol
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on NCT03848832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03848832.